Sign inJoin waitlistJoin the waitlist

Erica Stringer-Reasor

Vice Chair, Access and Engagement · University of Alabama Hospital

Credentials: · · · · · ·

History

Access and Engagement · University of Alabama Hospital
Present
University of Alabama Hospital
Present
University of Alabama Hospital
Present

Hematology and Medical Oncology
Tulane University School of Medicine
2011–2014
Internal Medicine
Tulane University School of Medicine
2008–2011
University of South Alabama College of Medicine
2004–2008

Research

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 759 citations
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 711 citations
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively…
JAMA Oncology · 2020 · 610 citations

Hope Rugo
20 papers
Rita Nanda
17 papers
Anthony Elias
16 papers
Angela DeMichele
14 papers
Claudine Isaacs
13 papers
Amy Clark
11 papers
Douglas Yee
11 papers
Laura Esserman
11 papers
Jo Chien
10 papers
AF
Andres Forero-Torres
9 papers
Anne Wallace
9 papers
HH
Hyo Han
9 papers

Grants

NCTN Deep South Research Consortium
National Cancer Institute · UG1
PI · $3.2M · University of Alabama at Birmingham
2019–2032
3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership
National Cancer Institute · U54
PI · $587.4K · University of Alabama at Birmingham
2005–2027

Clinical trials

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
University of Alabama at Birmingham
2019–2027
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Principal investigator · Terminated · Phase 2
University of Alabama at Birmingham
2019–2021
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
Principal investigator · Completed · Phase 1, Phase 2
University of Alabama at Birmingham
2015–2022
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029